Live
FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitiesNINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxEndpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsIlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo FinanceFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospectMIURA CO.,LTD.Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st
FierceBiotech 6. Dez. 2025

FDA panel votes against J&J's novel shunt implant for heart failure

FDA panel votes against J&J's novel shunt implant for heart failure

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.